Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.

Investigational New Drugs
K E BroekmanM Jalving

Abstract

Background Metformin use is associated with reduced cancer risk in epidemiological studies and has preclinical anti-cancer activity in ovarian cancer models. The primary objective of this phase I study was to determine the recommended phase II dose (RP2D) of metformin in combination with carboplatin/paclitaxel in patients with ovarian cancer. Secondary objectives were to describe safety and pharmacokinetics. Methods In this single-center trial the RP2D of metformin in combination with carboplatin area under the concentration-time curve (AUC) 6 and paclitaxel 175 mg/m2 every 3 weeks (q3w) in patients with advanced epithelial ovarian cancer was determined using a 3 + 3 escalation rule at three fixed dose levels: 500 mg three times daily (tds), 850 mg tds and 1000 mg tds. Metformin was commenced on day 3 of cycle 1 and continued until 3 weeks after the last chemotherapy administration. The RP2D was defined as the dose level at which 0 of 3 or ≤ 1 of 6 evaluable subjects experienced a metformin-related dose-limiting toxicity (DLT). Safety was assessed according to CTCAE v4.0. Plasma and serum samples for pharmacokinetic (PK) analyses were collected during treatment cycles 1 and 2. Results Fifteen patients with epithelial ovarian ca...Continue Reading

References

Mar 1, 1988·Journal of Clinical Pharmacology·S OguriR D Smyth
Sep 1, 1983·Diabetes Care·P DandonaA G Beckett
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
May 1, 1996·Clinical Pharmacokinetics·A J Scheen
Nov 1, 1996·The Journal of Clinical Endocrinology and Metabolism·K CusiR A DeFronzo
May 19, 2004·Expert Reviews in Molecular Medicine·Jacqueline HallRobert Brown
Jul 21, 2004·Cancer Cell·Reuben J ShawLewis C Cantley
Dec 21, 2005·The Journal of Nutrition·Yien-Ming KuoJoseph R Prohaska
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
May 23, 2008·Gynecologic Oncology·Walter H GotliebIlan Bruchim
Sep 18, 2009·Nature Reviews. Cancer·Karen H Vousden, Kevin M Ryan
Oct 31, 2009·Journal of Cellular and Molecular Medicine·R RattanV Shridhar
Sep 8, 2010·The New England Journal of Medicine·Ignace VergoteUNKNOWN NCIC Clinical Trials Group
Feb 8, 2011·Clinical Oncology : a Journal of the Royal College of Radiologists·C Herbert, P Cornes
May 3, 2011·Neoplasia : an International Journal for Oncology Research·Ramandeep RattanViji Shridhar
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 17, 2011·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jeroen J M A HendrikxJos H Beijnen
Apr 12, 2012·Molecular Cancer Therapeutics·Siqing FuRazelle Kurzrock
Apr 12, 2012·Diabetes·Lisa LogieGraham Rena
Jul 4, 2012·Oncology Reports·Buchu WuWen Di
Mar 19, 2013·European Journal of Pharmacology·Christos V Rizos, Moses S Elisaf
Aug 28, 2013·Expert Opinion on Investigational Drugs·Joud HajjarAung Naing
Jan 18, 2014·Biochemistry·Peter RepiščákMartin J Paterson
Mar 4, 2014·PloS One·Eoghainín Ó hAinmhireJoanna E Burdette
May 2, 2014·Frontiers in Oncology·Camillo PortaAlessandra Mosca
Feb 14, 2015·Gynecologic Oncology·Seiji MabuchiTomoyuki Sasano
Oct 6, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Rana SayedOsama Badary
Oct 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele ReniLorenzo Piemonti
Mar 26, 2016·Cancer Chemotherapy and Pharmacology·Muhammad R KhawajaAung Naing
Jun 6, 2016·Clinical Colorectal Cancer·Vanessa C MirandaRachel P Riechelmann
Jun 16, 2017·Investigational New Drugs·Remco J MolenaarJohanna W Wilmink

❮ Previous
Next ❯

Citations

Dec 2, 2020·International Journal of Molecular Sciences·Agnieszka KosowskaTomasz Francuz
Oct 24, 2020·International Journal of Molecular Sciences·Mariana NunesSara Ricardo

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Software Mentioned

KinFit
MWPharm
Excel
SPSS Statistics

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

World Journal of Oncology
Annamaria Di MariPaolo Tralongo
Endocrine Research
Michael StumvollStephan Matthaei
The New England Journal of Medicine
O B Crofford
Diabetes Care
Z T Bloomgarden
© 2021 Meta ULC. All rights reserved